Clinical trials: Optic Neuropathy, Anterior Ischemic
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis (SONIC-GCA) study will evaluate the performance of the optic nerve sheath diameter (ONSD), measured via ultrasound, to diagnose and monitor GCA.
- Conditions
- Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy, Optic Neuropathy, Ischemic
- Trial name
- SONIC-GCA (NCT05749094)
- Testing
- Optic nerve sheath ultrasound, Standardized GCA assessment
- Where
- 7 sites in Canada
- Volunteers
- 285 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Nonarteritic Anterior Ischemic Optic Neuropathy
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
This prospective randomized clinical study aims to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) injection in patients with acute non-arteritic anterior ischemic optic neuropathy (NAION).
- Trial name
- PRP-NAION (NCT07330713)
- Testing
- Autologous Platelet-Rich Plasma (PRP)
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Uludag University
Neuro-Ophthalmology, Optic Neuropathies
Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study
OCT-A and eco-colordoppler are technologies which enable optic nerve head (ONH) blood perfusion detection. The aim of the study is to assess ONH vascular and structural components in optic neuropathies with and without ONH edema…
- Conditions
- Neuro-Ophthalmology, Optic Neuropathies, Optic Atrophy, Hereditary, Leber, Optic Neuropathy, Anterior Ischemic
- Trial name
- FlowONH (NCT07075887)
- Volunteers
- 70 people
- Sponsor
- Barboni
Giant Cell Arteritis, Visual Impairment
Visual Involvement in Giant Cell Arteritis
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes.
- Conditions
- Giant Cell Arteritis, Visual Impairment, Central Retinal Artery Occlusion, Anterior Ischemic Optic Neuropathy
- Trial name
- Visu-GCA (NCT06500728)
- Testing
- Fluorescein and Indocyanine green Angiography, High-resolution Optical Coherence Tomography, Angio-Optical Coherence Tomography
- Where
- Italy
- Volunteers
- 762 people
- Sponsor
- ASST Fatebenefratelli Sacco
Anterior Ischemic Optic Neuropathy
Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy
Ischemic optic neuropathy is among the most common causes of serious impaired vision in the middle-aged and elderly population in the western world.
- Trial name
- NCT03401892
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
- Trial name
- NCT01260324
- Testing
- No intervention given in this observational study
- Volunteers
- 21,283 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Nonarteritic Anterior Ischemic Optic Neuropathy
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION.
- Trial name
- NCT03547206
- Testing
- RPh201 Cohort A, RPh201 Cohort B
- Where
- 15 sites in United States
- Volunteers
- 165 people
- Sponsor
- Regenera Pharma Ltd
Non Arteritic Anterior Ischemic Optic Neuropathy
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population.
- Trial name
- NCT02341560
- Testing
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg
- Where
- 85 sites in United States, Australia and 6 more
- Volunteers
- 732 people
- Sponsor
- Quark Pharmaceuticals
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma
Electric Stimulation of the Eye to Improve Vision After Trauma
Transcorneal Electrical Stimulation (TES) using the "OkuStim®" device delivers electrical impulses to damaged and/or diseased photoreceptor cells.
- Conditions
- Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
- Trial name
- TES (NCT02019927)
- Testing
- Transcorneal Electrical Stimulation
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Wills Eye
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION Treatment With Oral Prednisolone and Erythropoietin Injection
This randomized double-blind clinical trial is performed on all recent (within the last 5 days) NAION patients referred to hospitals affiliated to the Shahid Beheshti University of Medical Sciences, Iran.
- Trial name
- NAION (NCT03715881)
- Testing
- Oral prednisolone administration 50 mg, Intravenous Erythropoietin injection
- Where
- Iran
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Nonarteritic Anterior Ischemic Optic Neuropathy
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute…
- Trial name
- NCT01131104
- Testing
- PDE5 Inhibitors
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Eli Lilly and Company
Non-arteritic Anterior Ischemic Optic Neuropathy
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Clinical trial.gov Brief summary : Non-arteritic anterior ischemic optic neuropathy (NAION) is an optic neuropathy due to acute or subacute ischemic event of anterior optic nerve axons retrolaminar part that was vascularized by…
- Trial name
- NAION (NCT03046693)
- Testing
- Group A Citicoline 1000 mg oral tablet
- Where
- Indonesia
- Volunteers
- 38 people
- Sponsor
- Valen Chia
Anterior Ischemic Optic Neuropathy
Effect of EECP on Anterior Ischemic Optic Neuropathy
Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.
- Trial name
- AION (NCT01768260)
- Testing
- Enhanced external counterpulsation, Aspirin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy.
- Conditions
- Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy, Optic Neuropathy, Anterior Ischemic
- Trial name
- NCT01607671
- Testing
- Timolol maleate
- Where
- Canada
- Sponsor
- Fraser Health